Comey's testimony? U.K. elections? Eurozone news? These can be new buying opportunities, says Jim Cramer.
Rivals Kite Pharma and Novartis are still out in front, but updated efficacy and safety data from Juno's JCAR017 program in patients with aggressive non-Hodgkin's lymphoma are very competitive.
Insiders at Bioverativ, Juno Therapeutics and three other companies have been buying up shares of their own stock recently.